Tendinopathy Annual Evaluation Checklist

What Is Tendinopathy and Why Annual Evaluation Matters

Tendinopathy describes a failed healing response inside the tendon matrix, producing disorganized collagen, increased ground substance, and neovascularization rather than the clean fibre architecture seen in healthy tissue. The histological picture is one of tendinosis, not acute inflammation, a distinction that shapes every treatment decision. Annual evaluation matters because the natural history is not linear: a patient who is pain-free at month six may be loading beyond tendon capacity by month twelve, quietly accumulating structural damage before symptoms return.

A 2018 systematic review in the British Journal of Sports Medicine found a pooled 12-month recurrence rate of approximately 40 percent in Achilles and patellar tendinopathy when structured follow-up was absent. [1] Catching a silent relapse early, before the patient has abandoned their loading program, is the primary clinical goal of the annual review.

The Pathology Behind the Checklist

Healthy tendon collagen is arranged in parallel type-I collagen bundles. In tendinopathy, those bundles are replaced by type-III collagen, fibroblast proliferation, and increased proteoglycan accumulation. This matrix disorganisation reduces tensile strength by roughly 30 percent before any pain is reported, according to tendon biomechanics research published in the Journal of Orthopaedic Research. [2] The annual checklist is, in part, a structural audit that compares the patient's current tendon status against this baseline vulnerability.

Who Needs a Formal Annual Review

Any patient with a confirmed diagnosis of tendinopathy at the Achilles, patellar tendon, rotator cuff, or lateral epicondyle should receive a structured annual evaluation. Patients who have received one or more platelet-rich plasma (PRP) injections, corticosteroid injections, or off-label peptide protocols including BPC-157 require additional documentation review at each yearly visit to track both efficacy and safety signals over time.

Step 1: Pain and Functional Outcome Scoring

The annual review opens with validated patient-reported outcome measures. These provide an objective year-over-year comparison that clinical impression alone cannot replicate.

VISA Scores

The Victorian Institute of Sport Assessment (VISA) tools are the standard outcome instruments for tendinopathy. VISA-A measures Achilles tendinopathy; VISA-P measures patellar tendinopathy. Both are scored out of 100, with higher scores indicating better function. A score of 100 represents a fully asymptomatic, high-functioning tendon.

A 2001 validation study of the VISA-A in the British Journal of Sports Medicine confirmed a mean score of 96 in asymptomatic controls versus 49 in symptomatic Achilles tendinopathy patients. [3] At annual review, a VISA score drop of 10 or more points from the prior year warrants a full re-evaluation of loading program adequacy and a reassessment of contributing factors.

For the rotator cuff and lateral epicondyle, the DASH (Disabilities of the Arm, Shoulder and Hand) questionnaire and the Patient-Rated Tennis Elbow Evaluation (PRTEE) are the preferred instruments. The American Academy of Orthopaedic Surgeons endorses the DASH as a primary upper-extremity outcome measure. [4]

Visual Analogue Scale and Activity-Related Pain

Alongside VISA scores, record a Visual Analogue Scale (VAS) pain score specifically during the provocation test relevant to the tendon being evaluated. For the Achilles, this is the single-leg heel rise. For the patellar tendon, the single-leg decline squat produces the most reliable pain signal, as confirmed by a biomechanical study in the Scandinavian Journal of Medicine and Science in Sports showing 36 percent greater patellar tendon strain on the decline squat versus flat-surface squat. [5]

A post-activity VAS of 0-2/10 represents acceptable loading tolerance. Scores of 3-5/10 indicate load needs reduction. Scores above 5/10 indicate the current program is provoking pathological load and requires immediate modification.

Step 2: Load Tolerance and Exercise Program Audit

Load management is the single most evidence-supported intervention across all tendinopathy sites. The annual evaluation must audit whether the patient is progressing their load appropriately or has stagnated.

Assessing Current Loading Stage

The Silbernagel Combined Loading Program and the Alfredson eccentric protocol remain the two most cited structured loading programs for Achilles tendinopathy. Alfredson's original 1998 paper in the American Journal of Sports Medicine described 12 weeks of eccentric calf training producing a return to running in 15 of 15 patients who had previously failed conservative care. [6] At annual review, document which stage of a structured loading program the patient is currently following and whether they have progressed, plateaued, or regressed.

Heavy slow resistance (HSR) training has shown equivalence to eccentric training in a randomized controlled trial by Beyer et al. (2015, N=58) published in the American Journal of Sports Medicine, with both groups achieving significant VISA-A improvement at 12 weeks (eccentric: 22.4 points, HSR: 23.7 points). [7] If a patient has been on the same program for more than 16 weeks without measurable VISA improvement, the program should be restructured before the next annual visit.

Limb Symmetry Index Testing

Strength deficits between the affected and unaffected limb are a reliable surrogate for tendon loading capacity. The Limb Symmetry Index (LSI) compares performance on single-leg tasks between sides. A return-to-sport threshold of 90 percent LSI on heel-rise endurance testing (maximum repetitions, single leg) is widely cited in rehabilitation literature. [8]

At annual review, record:

• Maximum single-leg heel-rise repetitions (Achilles)
• Single-leg squat depth at pain-free range (patellar)
• Shoulder abduction peak force via handheld dynamometry (rotator cuff)

Document LSI scores as a percentage and flag any deficit greater than 15 percent for targeted strengthening before the next review cycle.

Training Load and Activity History

Tendinopathy is fundamentally a mismatch between tendon capacity and applied load. At annual review, ask the patient directly about changes in training volume, frequency, or type over the preceding 12 months. Rapid increases in running mileage, court-sport frequency, or occupational repetitive strain are the most common precipitants of relapse. A 2019 study in the British Journal of Sports Medicine found that a 10 percent weekly increase in running volume was the threshold above which Achilles tendinopathy risk increased significantly. [9]

Step 3: Imaging Review

Imaging in tendinopathy is confirmatory, not diagnostic. Pain and functional scores should drive clinical decisions; structural findings on ultrasound or MRI provide supporting context.

Ultrasound Findings to Document Annually

Greyscale ultrasound can identify tendon hypoechogenicity (disorganized matrix), tendon thickening, intrasubstance tears, and calcifications. Power Doppler ultrasound detects neovascularization, which correlates with the neural ingrowth believed to contribute to tendinopathy pain.

A prospective cohort study published in the British Journal of Sports Medicine (van Schie et al., 2010, N=89) found that tendon structure normalization on ultrasound tissue characterisation preceded symptom resolution by a mean of 8.3 weeks, suggesting structural healing lags behind the clinical picture. [10] At annual review, compare current ultrasound findings against the prior year's images. New or worsening hypoechogenicity in a previously stable tendon warrants increased clinical scrutiny even when VISA scores are unchanged.

When to Order MRI

MRI provides better spatial resolution for partial-thickness tears, bony insertional pathology, and bursal involvement. Order repeat MRI when:

• Ultrasound findings are inconclusive after a clinical deterioration
• Partial tear size needs to be measured before deciding on surgical referral
• Bone marrow oedema at the enthesis (insertional tendinopathy) requires characterisation

MRI findings of greater than 50 percent cross-sectional tendon disruption at the Achilles or patellar tendon should prompt orthopaedic surgical consultation, as per the American Academy of Orthopaedic Surgeons clinical practice guideline on Achilles tendon rupture. [11]

Step 4: Injection History and Off-Label Therapy Review

A thorough injection history is non-negotiable at annual review. The type, number, timing, and perceived efficacy of any injections received in the prior 12 months must be recorded.

Corticosteroid Injection: Cumulative Risk Audit

Corticosteroid injections provide short-term pain relief (4-6 weeks) but are associated with tendon weakening and a higher long-term recurrence rate compared to placebo. A Cochrane review by Gaujoux-Viala et al. Found that corticosteroid injection for lateral epicondylalgia produced superior pain relief at 6 weeks but significantly worse outcomes at 12 months versus physiotherapy and wait-and-see approaches. [12]

At annual review, document:

• Total lifetime corticosteroid injections at the affected tendon
• Time since last injection (minimum 6-week gap between injections is standard; some guidelines recommend 3 months)
• Any structural change on imaging attributable to steroid exposure

More than three lifetime corticosteroid injections at a single tendon site should trigger formal discussion of alternative management.

PRP Injection Outcomes

Platelet-rich plasma (PRP) is an autologous blood-derived product injected into the tendon to deliver concentrated growth factors including PDGF, TGF-beta, and VEGF. Evidence remains mixed. A randomized controlled trial by de Vos et al. (2010, N=54) published in JAMA found no significant difference between PRP and saline injection in VISA-A scores at 24 weeks in Achilles tendinopathy. [13] A subsequent meta-analysis in the American Journal of Sports Medicine (N=284 across six RCTs) found modest benefit in patellar tendinopathy specifically, with a mean VISA-P improvement of 12.4 points versus 6.8 for control at 6 months. [14]

At annual review, if the patient received PRP in the prior year, document the VISA score change from pre-injection baseline and compare it against the expected natural history improvement of 8-10 VISA points seen with exercise alone.

BPC-157 and Peptide Protocols

BPC-157 (body protection compound-157) is a synthetic pentadecapeptide derived from a gastric juice protein. It has demonstrated pro-angiogenic and collagen-synthesis effects in multiple animal tendon injury models, with studies showing accelerated Achilles tendon repair in rats at doses of 10 mcg/kg. [15] No published randomized controlled trials in humans have been completed as of mid-2025. BPC-157 is not FDA-approved for any indication, and its use in humans is considered off-label research-grade.

At annual review, any patient self-administering BPC-157 should have:

• Documented informed consent acknowledging the absence of human RCT data
• A clear treatment goal with a defined VISA endpoint (e.g., VISA-A improvement of >15 points at 12 weeks)
• Baseline and follow-up ultrasound to detect any adverse structural change
• Quarterly safety check-ins outside of the annual review cycle

The HealthRX Annual Tendinopathy Peptide Audit Framework recommends that off-label peptide use be re-evaluated at every yearly visit against the available evidence base, which may evolve as human trial data emerge.

Step 5: Red Flag Screening

Every annual evaluation must include a structured screen for red flags that shift the clinical pathway from conservative management to urgent referral.

Tendon Rupture Signs

Achilles tendon rupture produces a palpable gap, a positive Thompson test (absence of plantar flexion when the calf is squeezed with the patient prone), and sudden-onset severe pain. Partial tears may present subtly. Any patient reporting a sudden increase in tendon pain after a single activity, particularly with a pop or snap, requires same-day imaging rather than waiting for the annual review cycle. The incidence of complete Achilles rupture is approximately 18 per 100,000 person-years, with the highest rates in men aged 30-50 engaging in recreational sport. [16]

Metabolic and Systemic Contributors

Several systemic conditions predispose to tendinopathy and must be screened at annual review. Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) carry an FDA black-box warning for tendon rupture risk, including in patients with no prior tendon history. [17] Hypothyroidism, diabetes mellitus, and hyperlipidaemia all impair tendon collagen quality and should be assessed via TSH, HbA1c, and lipid panel at the annual visit if not recently tested. A 2013 study in Rheumatology (N=226) found that patients with hypercholesterolaemia had a 4.7-fold higher odds of tendinopathy compared to normocholesterolaemic controls. [18]

Statin use should also be noted: a pharmacovigilance analysis in Drug Safety found that statin-associated tendinopathy was the third most reported musculoskeletal adverse event after myalgia and myopathy. [19]

Step 6: Return-to-Sport and Work Readiness Assessment

The annual evaluation is an appropriate point to formally reassess whether the patient has met, or is progressing toward, return-to-sport or return-to-work criteria.

Objective Clearance Criteria

Return-to-sport clearance for lower-limb tendinopathy requires all of the following:

• VAS pain <2/10 during and 24 hours after sport-specific activity
• LSI >90% on the single-leg heel-rise test (Achilles) or single-leg decline squat (patellar)
• VISA score of 70 or above (a common clinical threshold, although 80+ is preferred for high-demand athletes)
• Absence of reactive tendinopathy signs (pain spiking above 5/10 during loading)

A prospective study in the British Journal of Sports Medicine (Rio et al., 2016, N=31) confirmed that athletes who returned to sport without meeting LSI criteria had a 2.6-fold higher re-injury rate at 12 months versus those who cleared all criteria. [20]

Occupational Tendinopathy Considerations

Lateral epicondyle and rotator cuff tendinopathy are the most common occupationally driven sites. For these patients, annual evaluation should include a functional capacity assessment specific to occupational demands: grip strength (lateral epicondyle), shoulder flexion endurance (rotator cuff), and review of any ergonomic modifications in the work environment. The National Institute for Health and Care Excellence (NICE) guidelines on lateral epicondylalgia recommend a structured ergonomic review as part of ongoing management. [21]

Step 7: Shared Decision-Making and Twelve-Month Plan

The final step of the annual evaluation is setting a documented, patient-specific plan for the next 12 months.

Goals to Set at Each Annual Review

Every annual evaluation should produce a written management plan that includes:

• A target VISA score for the next review period (e.g., from 62 to 75)
• A specified loading program (name, frequency, sets, reps) for the next 12 weeks
• Clear criteria for stepping up to injection therapy if the loading program fails
• A defined follow-up interval (typically 3 months for patients with active symptoms)

"The evidence consistently shows that exercise-based loading programs are the cornerstone of tendinopathy management. Without a structured, progressive load prescription, neither injections nor adjunct therapies achieve durable results," stated Dr. Jill Cook, Adjunct Professor at La Trobe University and a leading tendinopathy researcher, in the British Journal of Sports Medicine clinical commentary series. [22]

Escalation Pathway

When a patient fails two consecutive 12-week loading program cycles without meaningful VISA improvement (<10 points), the annual review should formally trigger a discussion of:

1. Ultrasound-guided PRP (particularly for patellar tendinopathy, where meta-analytic data are most supportive)
2. High-volume injection (saline plus corticosteroid) for Achilles peritendinous pain
3. Sclerosing injection targeting neovascular ingrowth under Doppler guidance
4. Surgical referral for partial or complete tendon tears confirmed on MRI

"Clinicians should resist the temptation to inject early. Injections at 6 weeks of symptoms, before a loading program has been adequately trialled, increase the long-term recurrence risk without improving 12-month outcomes," according to the 2023 British Journal of Sports Medicine editorial on tendinopathy consensus management. [23]

Annual Evaluation Summary Table

| Checklist Domain | Tool or Measure | Action Threshold | |---|---|---| | Pain scoring | VISA-A, VISA-P, DASH, PRTEE | Drop of >10 points triggers full re-evaluation | | Activity pain | VAS on provocation test | Score >5/10 requires load reduction | | Strength symmetry | Limb Symmetry Index | <90% flags strengthening deficit | | Imaging | Ultrasound (annual), MRI (if indicated) | New hypoechogenicity warrants scrutiny | | Injection history | Corticosteroid count, PRP record | >3 lifetime steroid injections triggers alternative review | | Off-label peptides | BPC-157 or similar | Quarterly safety check, documented consent | | Red flags | Thompson test, sudden pain | Same-day imaging if positive | | Metabolic screen | TSH, HbA1c, lipid panel | Treat underlying condition if abnormal | | Return criteria | VAS <2/10, LSI >90%, VISA >70 | All three required before sport clearance | | 12-month plan | Written loading program, VISA target | Document at every annual visit |